Recently, a phase II study was designed to assess the activity of the FGFR inhibitor AZD4547 in patients with FGFR1- and FGFR2-amplified breast, squamous lung, or stomach cancers, whose cancers had progressed following previous chemotherapy (NCT01795768). The gene discussed is FGFR1; the disease is gastric cancer.